Cadila Healthcare is currently trading at Rs. 246.60, up by 1.30 points or 0.53% from its previous closing of Rs. 245.30 on the BSE.
The scrip opened at Rs. 247.50 and has touched a high and low of Rs. 248.80 and Rs. 246.00 respectively. So far 5737 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 432.40 on 10-Sep-2018 and a 52 week low of Rs. 241.00 on 07-Jun-2019.
Last one week high and low of the scrip stood at Rs. 254.10 and Rs. 241.25 respectively. The current market cap of the company is Rs. 25112.41 crore.
The promoters holding in the company stood at 74.79%, while Institutions and Non-Institutions held 17.31% and 7.90% respectively.
Cadila Healthcare’s subsidiary-- Alidac Pharmaceuticals has received an Establishment Inspection Report (EIR) for manufacturing facility located at Pharmez, Ahmedabad.
The USFDA had conducted a Pre-Approval Inspection (PAI) for Doxorubicin Liposomal, a complex oncological injectable at Alidac, the injectable onco manufacturing facility, from March 18 to March 26, 2019. There was also a separate in-vitro BE inspection conducted by the Office of Study Integrity and Surveillance branch of the USFDA for the same product.
Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.
